Novo Nordisk And Eli Lilly prepare to bring obesity pills to India in 2027
- Novo Nordisk and Eli Lilly are preparing to launch oral obesity medicines in India during 2027.
- Novo’s oral Wegovy and Lilly’s orforglipron have reportedly been submitted to Indian regulators for approval.
- Novo Nordisk says many obesity patients prefer tablets over injections, supporting demand for oral treatments.
- Novo is also exploring childhood obesity pilots in India and seeking greater public-sector involvement.
Source: cnbc.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
